NCT04246918 (BCAA-CLD) is a NA clinical trial of Branched Chain Amino Acid in Chronic Liver Disease, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT04246918?

NCT04246918 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT04246918?

Interventions in NCT04246918: Branched Chain Amino Acid, Whey Protein concentrate powder.

What condition does NCT04246918 study?

NCT04246918 studies Chronic Liver Disease.

Is NCT04246918 still recruiting?

NCT04246918 is currently completed. Last updated 31 January 2023.

Last reviewed 2023-01-31 · How we verify

NCT04246918: BCAA-CLD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of BCAA Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in CLD Patients

Completed NA Last updated 31 January 2023

What this trial tests

NA trial testing Branched Chain Amino Acid in Chronic Liver Disease in 60 participants. Completed in 30 September 2022.

Timeline

1 June 2020

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 June 2020
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	1 location across India

Drugs / interventions tested

Branched Chain Amino Acid — full drug profile →
Whey Protein concentrate powder

Conditions studied

Chronic Liver Disease — all drugs for Chronic Liver Disease →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 60, any sex, with Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Loss of muscle mass (sarcopenia) is a major complication in a patient with cirrhosis, impacting the disease outcome, quality of life and survival. Cirrhotics lose muscle mass (MM) while waiting for liver transplant (LT) and even after LT, impacting the outcome of LT. Moreover, LT is elusive for majority of patients in India. The pathophysiology of muscle loss is complicated, multifactorial, interlinked and primarily nutrition driven, which gives clues for targeted therapeutic modalities other than feeding alone. Experimental studies have instilled faith in BCAA in successfully counteracting the pathogenesis of muscle loss. But there is lack of convincing data from clinical studies with direct evidence on muscle growth per se.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the JAK2/STAT3 Pathway-Can We Compare It to the Two Faces of the God Janus?
Jaśkiewicz A, Domoradzki T, Pająk B. · · 2020 · cited 32× · PMID 33158194 · DOI 10.3390/ijms21218261
Sarcopenia in chronic kidney disease: from bench to bedside.
Kim DW, Song SH. · · 2023 · cited 18× · PMID 37077132 · DOI 10.3904/kjim.2022.338
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease.
Kim Y. · · 2021 · cited 17× · PMID 33803020 · DOI 10.3390/life11030250

Verify or expand the search:

Other trials of Branched Chain Amino Acid

Trials testing the same drug.

NCT03891134 — Nutritional Intervention for Sarcopenia · NA · completed

Other recruiting trials for Chronic Liver Disease

Currently open trials in the same condition.

NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04246918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 31 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04246918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing